---
pmid: '32818467'
title: IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes
  Tumor Progression.
authors:
- Sadik A
- Somarribas Patterson LF
- Öztürk S
- Mohapatra SR
- Panitz V
- Secker PF
- Pfänder P
- Loth S
- Salem H
- Prentzell MT
- Berdel B
- Iskar M
- Faessler E
- Reuter F
- Kirst I
- Kalter V
- Foerster KI
- Jäger E
- Guevara CR
- Sobeh M
- Hielscher T
- Poschet G
- Reinhardt A
- Hassel JC
- Zapatka M
- Hahn U
- von Deimling A
- Hopf C
- Schlichting R
- Escher BI
- Burhenne J
- Haefeli WE
- Ishaque N
- Böhme A
- Schäuble S
- Thedieck K
- Trump S
- Seiffert M
- Opitz CA
journal: Cell
year: '2020'
full_text_available: false
doi: 10.1016/j.cell.2020.07.038
---

# IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.
**Authors:** Sadik A, Somarribas Patterson LF, Öztürk S, Mohapatra SR, Panitz V, Secker PF, Pfänder P, Loth S, Salem H, Prentzell MT, Berdel B, Iskar M, Faessler E, Reuter F, Kirst I, Kalter V, Foerster KI, Jäger E, Guevara CR, Sobeh M, Hielscher T, Poschet G, Reinhardt A, Hassel JC, Zapatka M, Hahn U, von Deimling A, Hopf C, Schlichting R, Escher BI, Burhenne J, Haefeli WE, Ishaque N, Böhme A, Schäuble S, Thedieck K, Trump S, Seiffert M, Opitz CA
**Journal:** Cell (2020)
**DOI:** [10.1016/j.cell.2020.07.038](https://doi.org/10.1016/j.cell.2020.07.038)

## Abstract

1. Cell. 2020 Sep 3;182(5):1252-1270.e34. doi: 10.1016/j.cell.2020.07.038. Epub 
2020 Aug 19.

IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor 
Progression.

Sadik A(1), Somarribas Patterson LF(2), Öztürk S(3), Mohapatra SR(1), Panitz 
V(4), Secker PF(5), Pfänder P(1), Loth S(6), Salem H(5), Prentzell MT(5), Berdel 
B(5), Iskar M(3), Faessler E(7), Reuter F(5), Kirst I(5), Kalter V(3), Foerster 
KI(8), Jäger E(9), Guevara CR(9), Sobeh M(10), Hielscher T(11), Poschet G(12), 
Reinhardt A(13), Hassel JC(14), Zapatka M(3), Hahn U(7), von Deimling A(13), 
Hopf C(9), Schlichting R(15), Escher BI(15), Burhenne J(8), Haefeli WE(8), 
Ishaque N(16), Böhme A(17), Schäuble S(18), Thedieck K(19), Trump S(20), 
Seiffert M(3), Opitz CA(21).

Author information:
(1)DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 
69120 Heidelberg, Germany; Faculty of Bioscience, Heidelberg University, 69120 
Heidelberg, Germany.
(2)DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 
69120 Heidelberg, Germany; Faculty of Bioscience, Heidelberg University, 69120 
Heidelberg, Germany; Department of Biochemistry, School of Medicine, University 
of Costa Rica (UCR), 11501-2060 San José, Costa Rica.
(3)Molecular Genetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, 
Germany.
(4)DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 
69120 Heidelberg, Germany; Neurology Clinic and National Center for Tumor 
Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany.
(5)DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 
69120 Heidelberg, Germany.
(6)Department of Environmental Immunology, Helmholtz Centre for Environmental 
Research-UFZ, 04318 Leipzig, Germany; Institute of Organic Chemistry, Technical 
University Bergakademie Freiberg, 09596 Freiberg, Germany.
(7)Jena University Language & Information Engineering (JULIE) Lab, 
Friedrich-Schiller-University Jena, 07743 Jena, Germany.
(8)Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg 
University Hospital, 69120 Heidelberg, Germany.
(9)Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim 
University of Applied Sciences, 68163 Mannheim, Germany.
(10)Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, 
69120 Heidelberg, Germany; AgroBioSciences Research Division, Mohammed VI 
Polytechnic University, 43150 Ben-Guerir, Morocco.
(11)Division of Biostatistics, German Cancer Research Center (DKFZ), 69120 
Heidelberg, Germany.
(12)Centre for Organismal Studies (COS), University of Heidelberg, 69120 
Heidelberg, Germany.
(13)Department of Neuropathology, Institute of Pathology, Heidelberg University 
Hospital, and Clinical Cooperation Unit Neuropathology, German Consortium for 
Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), 
69120 Heidelberg, Germany.
(14)Department of Dermatology and National Center for Tumor Diseases, Heidelberg 
University Hospital, 69120 Heidelberg, Germany.
(15)Department of Cell Toxicology, Helmholtz Centre for Environmental 
Research-UFZ, 04318 Leipzig, Germany.
(16)Center for Digital Health, Charité-Universitätsmedizin Berlin, corporate 
member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin 
Institute of Health (BIH), 10117 Berlin, Germany.
(17)Department of Ecological Chemistry, Helmholtz Centre for Environmental 
Research-UFZ, 04318 Leipzig, Germany.
(18)Jena University Language & Information Engineering (JULIE) Lab, 
Friedrich-Schiller-University Jena, 07743 Jena, Germany; Systems Biology and 
Bioinformatics, Leibniz Institute for Natural Product Research and Infection 
Biology-Hans Knöll Institute, 07745 Jena, Germany.
(19)Institute of Biochemistry and Center for Molecular Biosciences Innsbruck, 
University of Innsbruck, 6020 Innsbruck, Austria; Department of Pediatrics, 
University of Groningen, University Medical Center Groningen, 9700 RB Groningen, 
The Netherlands; Department of Neuroscience, School of Medicine and Health 
Sciences, Carl von Ossietzky University Oldenburg, 26129 Oldenburg, Germany.
(20)Molecular Epidemiology Unit, Charité-Universitätsmedizin Berlin, corporate 
member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin 
Institute of Health (BIH), 10117 Berlin, Germany.
(21)DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), 
69120 Heidelberg, Germany; Neurology Clinic and National Center for Tumor 
Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany. Electronic 
address: c.opitz@dkfz.de.

Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites 
enhances tumor malignancy and suppresses anti-tumor immunity. The context 
specificity of AHR target genes has so far impeded systematic investigation of 
AHR activity and its upstream enzymes across human cancers. A pan-tissue AHR 
signature, derived by natural language processing, revealed that across 32 tumor 
entities, interleukin-4-induced-1 (IL4I1) associates more frequently with AHR 
activity than IDO1 or TDO2, hitherto recognized as the main Trp-catabolic 
enzymes. IL4I1 activates the AHR through the generation of indole metabolites 
and kynurenic acid. It associates with reduced survival in glioma patients, 
promotes cancer cell motility, and suppresses adaptive immunity, thereby 
enhancing the progression of chronic lymphocytic leukemia (CLL) in mice. Immune 
checkpoint blockade (ICB) induces IDO1 and IL4I1. As IDO1 inhibitors do not 
block IL4I1, IL4I1 may explain the failure of clinical studies combining ICB 
with IDO1 inhibition. Taken together, IL4I1 blockade opens new avenues for 
cancer therapy.

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

DOI: 10.1016/j.cell.2020.07.038
PMID: 32818467 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of Interests Three patent 
application families (PCT/US2020/025560, PCT/EP2020/060259, and EP19214890.6) 
have been filed on aspects of the described work. M. Seiffert. and C.A.O. 
receive and/or are planning to receive research funding from commercial 
organizations, like Bayer. C.A.O. is listed as inventor on PCT/EP2012/067504.
